Articles tagged with Amyotrophic Lateral Sclerosis
Dr. Vidhya Rangaraju has received a $1.2 million grant from the Chan Zuckerberg Initiative to investigate disrupted energy supply in neurons causing cognitive decline in ALS. Her lab will use super-resolution microscopy and biosensors to study metabolic disruptions in ALS.
Researchers developed a drug that triggers the destruction of damaged mitochondria, restored motor function in aging mice with ALS-like symptoms. The results show promising promise for treating neurodegenerative diseases like Parkinson's and Alzheimer's disease.
Researchers developed an environmental risk score to assess ALS risk and survival using a blood sample, associating several individual pollutants with disease risk. A mixture of pesticides in the blood significantly increased ALS risk, with those in the highest group having twice the risk as those in the lowest.
A new national ALS research consortium, Access for All in ALS, has been launched with a $16.7 million NIH award. The consortium will include 34 clinical sites nationwide and generate a longitudinal biorepository linked to detailed clinical information.
Dr. Qihui Zhou aims to investigate the role of immune cells in ALS and FTD with a focus on the C9orf72 gene mutation, potentially leading to better treatments.
A promising drug candidate CDNF has been found to prolong the lifespan of ALS patients and alleviate symptoms in rats and mice. The study suggests that CDNF may rescue motoneurons by reducing ER stress response and cell death.
A recent study found that over 70% of ALS patients and their caregivers are not disaster-prepared, highlighting the need for improved measures. The research also revealed significant gaps in equipment and knowledge among respondents, including ventilator users.
The new guidelines provide a framework for genetic testing and counseling, recommending comprehensive testing and gene-targeted therapies for all persons with ALS. The guidelines aim to improve access and standardize practice among neurologists and genetic counselors.
Researchers at the University of Sydney have developed a nanoscale optical technique to monitor protein aggregates forming in cells, which can lead to neurodegenerative diseases such as Alzheimer's and ALS. The study provides a new window into the transition of proteins from liquid to solid phase.
Scientists have successfully restored damaged nerve-to-muscle connections in a highly aggressive mouse model of amyotrophic lateral sclerosis (ALS) using grafted replacement motor neurons and optical nerve stimulation. The treatment improved muscle contraction force by over 13-fold, suggesting its potential for treating ALS patients.
Researchers at OHSU identified a type of monoclonal antibody that can slow the progression of amyotrophic lateral sclerosis (ALS) by modulating immune cells. The study used a mouse model and confirmed results in human brains affected by ALS, revealing a promising potential treatment for this fatal neurodegenerative disease.
A study published in Neuron reveals that hundreds of proteins and mRNA molecules are found in the wrong place in nerve cells affected by Motor Neurone Disease, a condition that causes paralysis. The researchers found that mislocalisation affects many more proteins than first thought, especially those involved in RNA binding.
New research suggests targeting autoimmune inflammation associated with ALS could be a promising approach. The study found that two drugs, including one already approved for multiple sclerosis, reduced the expression of inflammatory proteins in ALS patients' immune cells.
Researchers found that people with ALS who consume more omega-3 fatty acids like alpha-linolenic acid have a slower physical decline, a slightly extended survival, and lower risk of death. Omega-6 fatty acids like linoleic acid also showed promise in reducing mortality risk.
A new study led by Harvard T.H. Chan School of Public Health found that consuming omega-3 fatty acids, particularly alpha-linolenic acid, may help slow the progression of disease in patients with amyotrophic lateral sclerosis (ALS). Higher blood levels of ALA were associated with a slower disease progression and lower risk of death.
Researchers developed a polygenic scoring system to predict ALS disease risk, improving case status prediction in Michigan and Spain. The system takes into account common genetic variants and explains 4.1% of ALS cases caused by genetic factors.
Research at Umeå University reveals unique muscle fibers in extraocular muscles are resistant to ALS and increase in proportion when other fibers decrease. This finding could lead to new treatment strategies for slowing down the disease.
Researchers developed MOVA to evaluate the pathogenicity of missense variants based on their structural position. The new method showed superior performance in predicting pathogenicity, especially for hotspot mutations in ALS-causing genes like TARDBP and FUS.
A study by CU Boulder researchers suggests that the ancient virus-like protein PEG10 may contribute to the development of ALS by interfering with brain and nerve cell communication. The findings provide a promising new target for treating the underlying cause of the fatal disease.
Researchers found that ropinirole is safe and effective in slowing ALS progression, with patients showing improved physical activity and muscle strength after treatment. The study suggests that the method of growing motor neurons from patient-derived stem cells could be used to predict a patient's response to the drug.
Researchers found reduced editing efficiency of GluA2 mRNA in ALS patients' cerebrospinal fluid, correlating with longer disease duration and advanced symptoms. This discovery could lead to the development of therapies targeting RNA editing for treatable ALS cases.
A study published in Neurobiology of Disease suggests that targeting the sigma-1 receptor and ATAD3A protein may prevent mitochondrial dysfunction in ALS. The researchers found that this approach could lead to a novel therapeutic strategy for neurodegenerative diseases.
Researchers genetically engineered neural progenitor cells to release a neuroprotective protein, preventing neuron death in animal models of ALS and retinal disease. Engineered NPCs successfully preserved vision in rats with retinal disease.
Cedars-Sinai investigators have discovered a novel way to treat amyotrophic lateral sclerosis (ALS) and retinitis pigmentosa using human induced pluripotent stem cells. The new approach uses cells derived from iPSCs that are renewable, scalable, and can delay disease progression in rodents.
Researchers are investigating whether faecal microbiota transplantation can modulate the immune reaction and alter gut microbiota in early-stage ALS patients. The trial aims to investigate the relationship between specific gut bacteria and their action on immune system cells.
A simple blood test for ALS has been developed using microRNA analysis, which can accurately identify patients with the disease. The test uses a unique protein called L1CAM to concentrate diagnostic particles from extracellular vesicles in the bloodstream.
Research reveals that cold activates cellular cleansing mechanisms that break down protein clumps, preventing age-related diseases like Alzheimer's and Parkinson's. By modulating proteasome activity, scientists have found a potential therapeutic target for aging and related neurodegenerative disorders.
Researchers have created wearable microscopes to produce high-definition, real-time images of mouse spinal cord activity across previously inaccessible regions. This technology enables unprecedented insight into the neural basis of sensations and movement in healthy and disease contexts.
A team of researchers has discovered a protein deficiency in the neurons of patients with neurodegenerative diseases, such as ALS and Alzheimer's disease. They have developed an approach to fix this deficiency using antisense oligonucleotides that can correct abnormal RNA processing and restore stathmin-2 protein levels.
The American College of Chest Physicians released a clinical practice guideline on respiratory management for patients with neuromuscular weakness, providing evidence-based recommendations for mouthpiece ventilation and airway clearance therapies. The guideline aims to improve care for this vulnerable population.
The study reveals that gasdermin E drives changes in neurons that contribute to disease progression, leading to mitochondrial damage and axon degeneration. Inactivating gasdermin E prevents cellular damage and delays the progression of ALS in mice.
A study found that RNA methylation plays a pivotal role in TDP-43-related neurodegeneration in ALS. The researchers observed highly abundant RNA methylation in the end-stage tissues of patients with ALS. This discovery opens up new avenues for research into the disease, which is linked to environmental exposure.
Researchers have generated large-scale muscle-controlling nerve cells from ALS patients, revealing striking differences in gene expression between males and females. The study, published in Neuron, used over 450 lines of stem cells to create motor neurons that can potentially lead to the development of new therapeutics.
Researchers at USC Keck School of Medicine have identified two new avenues for treating diverse forms of ALS by suppressing genes and inhibiting proteins. The findings suggest that targeting SYF2 gene suppression and PIKFYVE kinase inhibition may lead to broadly effective treatments for the disease.
A team of researchers from Harvard and MGH developed a soft robotic wearable capable of significantly assisting upper arm and shoulder movement in people with ALS. The device improved range of motion, reduced muscle fatigue, and increased performance of tasks like holding or reaching for objects.
Scientists have developed a technique to detect RNA structures in live cells, shedding light on the role of G-quadruplexes in neurodegenerative diseases. The method uses fluorescent spectroscopy and resolves existing limitations in studying these structures in real-time.
A new study has identified distinct patterns of circular RNA expression in human ALS muscle tissue, which display disease-specific gradients and could inform about neuromuscular molecular programs in ALS. The research reveals that specific circRNAs are elevated in ALS muscle biopsies but reduced in spinal cord samples from ALS patients.
Scientists at the CRCHUM have identified a protective probiotic for ALS, Lacticaseibacillus rhamnosus HA-114, that prevents neurodegeneration in the C. elegans worm model. The probiotic helps reduce motor disorders and restore balance to impaired energy metabolism, leading to a decrease in neurodegeneration.
A retrospective study found that multidisciplinary care for ALS significantly decreases multiple emergency hospitalizations and improves survival rates. The study compared patients with ALS treated at a multidisciplinary clinic versus a traditional General Neurology Clinic and showed improved outcomes.
Researchers have discovered a way to predict the course of ALS by measuring immune cells in cerebrospinal fluid. A high proportion of effector T cells is associated with low survival rates, while activated regulatory T cells indicate a protective role against rapid disease progression.
A new hallmark of ALS has been identified, revealing that loss of the RNA processing protein SFPQ leads to motor neuron degeneration. Defective mRNAs accumulate in axons and interfere with normal function, pointing to a possible new target for therapy.
Scientists at UF Scripps Biomedical Research have developed a potential medicine for ALS and dementia by eliminating disease-causing RNA segments. The compound restored neuron health in lab experiments and rescued mice with the disease.
A team from California Institute of Technology has developed a brain-machine interface device that can predict internal speech in patients with tetraplegia. The device, trained on single neurons in the supramarginal gyrus, achieved accuracy up to 91% in predicting eight words.
A collaborative study reveals how genes controlling blood vessel cells influence motor neuron development, allowing them to navigate the body's systems. The discovery sheds light on diseases such as ALS and SMA, where motor neuron connections are destroyed.
Researchers identified a kinase molecule that directs microglia activity, potentially treating neurodegenerative diseases like Alzheimer's and MS. The molecule, called spleen tyrosine kinase, targets plaque buildup and debris accumulation in the brain.
A new study aims to diagnose severe neurodegenerative diseases like ALS and FTD with the help of speech tests. AI can analyze subtle nuances of speech patterns, including pauses, speed, and melodic aspects, to detect early changes.
Researchers at USF Health successfully tested a protein that activates a unique pathway in cells to increase survival and protect endothelial cells from toxic substances. The study reveals the potential of apolipoprotein A1 as a novel therapeutic for ALS patients, with the goal of slowing disease progression and alleviating symptoms.
A small test group has shown that using a patient's own cells in combination with regulatory T-lymphocyte and IL-2 treatment can safely and effectively slow or halt the progression of amyotrophic lateral sclerosis (ALS). This treatment approach was found to be tolerable and biologically active over a period of one year.
Research has found that former Scottish international rugby union players are at a significantly increased risk of developing neurodegenerative diseases, including dementia and motor neurone disease. The study's findings suggest that strategies to reduce head impact and traumatic brain injury in all sports are necessary.
Researchers have identified a new marker for predicting the clinical outcome of patients with Amyotrophic Lateral Sclerosis (ALS) by analyzing brain flexibility during rest. The study found that brains with more flexible functional repertoires tend to have better clinical outcomes.
A new study found that arbitrary age limits and rules on genetic testing for amyotrophic lateral sclerosis (ALS) could be missed, leading to thousands of potential cases going undetected. The researchers argue that genetic testing should be open to all patients with ALS, regardless of age or family history.
A phase 3 clinical trial showed tofersen reduces SOD1 and neurofilament light protein levels, slowing down disease progression. Longer-term use may help stabilize muscle strength and control in people with genetic ALS.
The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.
A team of researchers has designed in silico molecular probes to track the progress of a misbehaving protein linked to neurodegenerative diseases like ALS and FTD. The probes can detect TDP-43 aggregates at high resolution, paving the way for early diagnosis.
A novel stem cell-gene therapy has been shown to be safe in humans, with no serious side effects reported in the first trial. The treatment targets motor neurons that die in patients with amyotrophic lateral sclerosis (ALS), a fatal neurological disorder.
A team of researchers from Ritsumeikan University in Japan has elucidated the mechanism behind the liquid-solid phase transition of FUS protein that leads to ALS. They discovered a new therapeutic target, arginine, which suppresses FUS aggregation and could delay ALS progression.
A study investigated the frequency and characteristics of non-motor symptoms in ALS patients, finding over 90% experienced symptoms such as fatigue, pain, and sleep disorders. These symptoms reduced QoL even when motor symptoms were mild, highlighting their importance to consider.
A new study finds that the drug terazosin has shown protective effects on motor neurons in models of motor neuron disease (MND), including zebrafish, mice and stem cell models. Researchers hope to launch a full clinical trial if the drug proves successful in a feasibility study involving 50 patients.
A team of researchers has discovered a protein called NOVA1 that displays pathological characteristics in ALS patients at an early stage. This finding could lead to the development of new therapy concepts and potentially enable early detection of the disease.
Researchers found altered cell-mediated immune function in ALS patients and a novel treatment approach using bone marrow transplants. The study suggests that abnormal CD8 T-cell response contributes to motor neuron degeneration.